Shanghai Junshi Biosciences Co., Ltd. (“Junshi Bio”) disclosed that shareholder Shanghai Tanying Investment Partnership (LP) intends to trim its holding by up to 20.53 million A-shares—equivalent to 2.00% of the company’s outstanding share capital—between 21 September 2026 and 20 December 2026.

Shanghai Tanying currently owns 38.93 million A-shares, representing 3.79% of Junshi Bio’s 1.03 billion outstanding shares. All of these shares were acquired prior to the company’s STAR Market IPO and have been freely tradable since 15 July 2021, when the original lock-up expired.

Proposed disposal mechanics • Volume: Maximum 10.27 million shares via centralized bidding and 10.27 million shares via block trades; aggregate disposals capped at 20.53 million shares (2% of share capital). • Timing: Sales may commence after 15 trading days from disclosure, running from 21 September 2026 to 20 December 2026. • Pricing: Transaction prices will be determined by market conditions; if ex-rights or ex-dividend events arise, the number of shares subject to reduction will be adjusted accordingly.

Regulatory framework and prior undertakings Shanghai Tanying qualifies for venture-capital shareholder reduction rules, which limit disposals to 1% of share capital via centralized bidding or 2% via block trades within any 60-day window. The fund has reiterated its commitment to previously disclosed IPO lock-up and price-floor undertakings, including the requirement that any A-share sales within two years of lock-up expiry cannot be below the IPO issue price (adjusted for corporate actions).

Historical selling activity Over the past 12 months Shanghai Tanying has executed two reductions: • 12.00 million shares (1.17% of share capital) from 5–22 September 2025 at RMB 43.13–48.46 per share. • 20.53 million shares (2.00% of share capital) from 8 June–19 August 2026 at RMB 28.73–39.87 per share.

Concert-party holdings Including two affiliated funds—Loyal Valley Capital Advantage Fund II LP and LVC Renaissance Fund LP—the concert-party group holds 54.68 million shares, equal to 5.33% of Junshi Bio’s share capital. The current plan involves only Shanghai Tanying’s stake; concert-party members did not announce parallel reductions.

Corporate impact and risk disclosure The company stated that the planned reduction will not trigger a change in control. Final execution remains contingent on market conditions, and the timing, price and exact volume of sales may vary within the disclosed parameters. Junshi Bio affirmed that all reductions will adhere to the Securities Law, Shanghai Stock Exchange rules and the specific provisions governing venture-capital shareholder exits.

Junshi Bio’s board pledged timely disclosure of any transactions executed under the plan, and advised investors to consider potential market fluctuations and regulatory requirements when assessing the implications of the contemplated share sales.